XL-PROTEIN
LIVE

Serial Number

79289202

Owner

XL-protein GmbH

Attorney

Anthony G. Craig

Filing Date

May 18, 2020

Add to watchlist:

No watchlists yet
View on USPTO

XL-PROTEIN Trademark

Serial Number: 79289202 • Registration: 6617137

XL-PROTEIN is a trademark filed by XL-protein GmbH on May 18, 2020. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently registered and active.

Owner Contact Info

XL-protein GmbH (5 trademarks)

Lise-Meitner-Str. 30
Freising 85354 , DE

Entity Type: 03

Trademark Details

Filing Date

May 18, 2020

Registration Date

January 18, 2022

Published for Opposition

November 2, 2021

Goods & Services

Pharmaceutical, medical and veterinary preparations for the treatment of growth deficiencies, inflammation, infections, obesity, diabetes, malignancies, metabolic diseases, cancer, cardiovascular diseases, diseases of the CNS, eye diseases or bone diseases; Pharmaceutical preparations for the treatment of growth deficiencies, inflammation, infections, obesity, diabetes, malignancies, metabolic diseases, cancer, cardiovascular diseases, diseases of the CNS, eye diseases, or bone diseases and diagnostic reagents for use in medicine and dentistry; Test kit reagents for use in medicine and dentistry; Chemical, biochemical and biotechnological preparations for medical and diagnostic use, namely reagents for medical purposes and solvents for sample preparation, modification and manipulation of cells as well as for use in methods for labeling, separation, isolation, purification, multiplication and analysis of biopolymers, especially nucleic acids, proteins, macromolecules and biologically active substances for medical diagnostic use; Drugs for preventive, curative and palliative purposes, namely for the treatment of growth deficiencies, inflammation, infections, obesity, diabetes, malignancies, metabolic diseases, cancer, cardiovascular diseases, diseases of the CNS, eye diseases, or bone diseases; Diagnostic medical biomarkers, especially for preventive, diagnostic, prognostic or predictive use; Medical preparations, namely, kits for use in medical laboratories, especially for preventive, diagnostic, prognostic or predictive use composed of proteinaceous reagents for medical purposes; Biomolecules for medical use, namely, for binding of active agents in the field of treatment of growth deficiencies, inflammation, infections, obesity, diabetes, malignancies, metabolic diseases, cancer, cardiovascular diseases, diseases of the CNS, eye diseases, or bone diseases; Medical preparations for use in medical diagnostic for the treatment of growth deficiencies, inflammation, infections, obesity, diabetes, malignancies, metabolic diseases, cancer, cardiovascular diseases, diseases of the CNS, eye diseases, or bone diseases; Chemical and biological preparations for medical and diagnostic purposes for the treatment of growth deficiencies, inflammation, infections, obesity, diabetes, malignancies, metabolic diseases, cancer, cardiovascular diseases, diseases of the CNS, eye diseases, or bone diseases

Chemical and biochemical preparations for use in biochemical research laboratories, in chemical research laboratories, in biotechnological research laboratories or in pharmaceutical research laboratories, other than for medical and veterinary use, as well as for industrial and scientific use

Scientific and technological services and research, namely, scientific research, analysis, and testing, and research all in the field of chemistry, genetics, biology, biotechnology and biochemistry; Medical or scientific laboratory services, namely, testing services in the field of DNA, RNA as well as protein expression, detection and analysis and design relating thereto, especially in the field of chemistry, genetics, biology, biotechnology and biochemistry; Services of a chemical and biochemical scientific or medical laboratory; Technological services, namely, technical processing in the nature of product development and technical scientific analysis of biomaterials and medically relevant data especially for scientific and industrial research

Filing History

FINAL DECISION TRANSACTION PROCESSED BY IB
Jul 18, 2022 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Jun 27, 2022 FICS
FINAL DISPOSITION PROCESSED
Jun 27, 2022 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Apr 18, 2022 FICR
REGISTERED-PRINCIPAL REGISTER
Jan 18, 2022 R.PR
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Jan 1, 2022 OPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Dec 15, 2021 OPNS
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Dec 15, 2021 OPNR
NOTIFICATION PROCESSED BY IB
Nov 8, 2021 GPNX
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Nov 2, 2021 NPUB
PUBLISHED FOR OPPOSITION
Nov 2, 2021 PUBO
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Oct 13, 2021 OPNS
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Oct 13, 2021 OP2R
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Oct 13, 2021 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Sep 29, 2021 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Sep 28, 2021 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Sep 28, 2021 CRFA
TEAS REQUEST FOR RECONSIDERATION RECEIVED
Sep 28, 2021 ERFR
NOTIFICATION OF FINAL REFUSAL EMAILED
Mar 30, 2021 GNFN
FINAL REFUSAL E-MAILED
Mar 30, 2021 GNFR
FINAL REFUSAL WRITTEN
Mar 30, 2021 CNFR
TEAS/EMAIL CORRESPONDENCE ENTERED
Mar 10, 2021 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Mar 9, 2021 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Mar 9, 2021 TROA
REFUSAL PROCESSED BY IB
Oct 4, 2020 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Sep 14, 2020 RFCS
REFUSAL PROCESSED BY MPU
Sep 14, 2020 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Aug 18, 2020 RFCR
NON-FINAL ACTION WRITTEN
Aug 17, 2020 CNRT
ASSIGNED TO EXAMINER
Aug 14, 2020 DOCK
APPLICATION FILING RECEIPT MAILED
Jul 14, 2020 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jul 10, 2020 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Jul 9, 2020 REPR